课题基金 / 基金详情

CORRECTION OF INHERITED PROTEIN DEFICIENCEIS BY GENE THERAPY

CORRECTION OF INHERITED PROTEIN DEFICIENCEIS BY GENE THERAPY
通过基因疗法纠正遗传性蛋白质缺陷
批准号:
5203708
负责人:
E I GINNS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

E I GINNS的其他基金

相关文献

中文摘要
翻译
遗传性疾病中正常和异常蛋白质的表征 影响神经系统允许分离cDNA和基因组 可用于使用基因纠正遗传性蛋白质缺陷的DNA 疗法 特别适合于基因治疗的初步尝试是 这些疾病(如戈谢病,最常见的 鞘脂病),其中全身和神经系统的表现 这些疾病是骨髓衍生异常的结果, 细胞,如巨噬细胞。 在这种情况下,正常的 特定组织或骨髓祖细胞的基因是一种 合理的治疗方法。 利用溶酶体疾病戈谢病 疾病作为模型,我们利用逆转录病毒载体转移和表达 小鼠和Gaucher患者细胞系中人葡糖脑苷脂酶。 受体介导的基因转移到组织中是另一种策略, 研究了 本研究的初步目标是应用 非神经元病表型的基因治疗。 转基因动物 利用胚胎中的靶向同源重组开发模型, 用干细胞制造人类疾病的小鼠模型。 录病毒 介导的神经递质合成酶的转移, 用于纠正多巴缺乏状态的酪氨酸羟化酶也 研究了作为L-DOPA仓库的有害操作细胞 释放正在开发用于移植到神经系统中。 当我们对遗传性疾病的发病机制的理解 神经和精神疾病的改善,并作为逆转录病毒介导的 基因在特定组织和细胞中的表达变得越来越多, 可以预见的是,我们可以将基因治疗的应用扩展到治疗 影响神经系统的特定疾病。
英文摘要
The characterization of normal and abnormal proteins in genetic disorders affecting the nervous system permits the isolation of cDNA and genomic DNA that can be used to correct inherited protein deficiencies using gene therapy. Particularly suited for initial attempts at gene therapy are those disorders (such as Gaucher disease, the most common sphingolipidosis) in which the systemic and neurologic manifestations of the disorder are the consequence of abnormalities of bone marrow derived cells, like the macrophage. In these instances the transfer of normal genes to either specific tissue or bone marrow progenitor cells is a rationale therapeutic approach. Using the lysosomal disorder Gaucher disease as a model, we utilize retroviral vectors to transfer and express human glucocerebrosidase in mouse and Gaucher patient cell lines. Receptor mediated gene transfer into tissues is another strategy being investigated. The initial goal of this research is the application of gene therapy to the non-neuronopathic phenotypes. Transgenic animal models are developed using targeted homologous recombination in embryonic stem cells to generate mouse models of human disease. Retroviral mediated transfer of neurotransmitter synthesizing emzymes such as tyrosine hydroxylase for the correction of DOPA deficiency states is also studied. Recombinantly manipulated cells that act as depots of L-DOPA release are being developed for transplantation into the nervous system. When our understanding of the pathogenetic mechanisms of inherited neurologic and psychiatric diseases improves and as retroviral-mediated expression of genes in specific tissues and cells becomes more predictable, we can extend the use of gene therapy to treatment of selected disorders affecting the nervous system.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MOLECULAR GENETICS OF LYSOSOMAL DISORDERS
MOLECULAR GENETIC STUDIES OF THE MUCOPOLYSACCHARIDOSES
GENE REGULATION WITHIN THE NERVOUS SYSTEM
STUDIES OF GAUCHER DISEASE AND OTHER NEUROGENETIC DISORDERS TOWARD GENE THERAPY